U.S. prosecutors are probing Valeant Pharmaceuticals over how it prices and distributes drugs, the Canadian pharma giant revealed late Wednesday.
And artificial intelligence will be hot for Chinese consumers, but 3-D printing will be all the rage in Europe.
James West, senior healthcare analyst for Results Healthcare, talks about biotech stocks and explains the differences biotech and pharmaceutical companies.
Bill Doyle, Executive Chairman, NovoCure, discusses the company's difficult debut--shares opened at $20.16, below the $22 IPO price.
With health care, financials and energy sectors all embattled, what should investors expect going into the fourth quarter and 2016?
Biotech's have had a very bad week, but the IBB has recovered a bit today. What's behind all the volatility, with Fed Hassan, Warburg Pincus, and CNBC's Meg Tirrell.
With the biotechnology sector tumbling, is this temporary? Or the beginning of a downward slide? Analysts weigh in.
David Seaburg, Cowen & Company, Jerry Castellini, CastleArk Management, discuss the biotech sector as the IBB heads into bear market territory.
The IBB, biotech ETF has officially entered bear market territory, and has fallen below the level where it was after the flash crash. CNBC's Brian Sullivan and Melissa Lee discuss.
CNBC's Meg Tirrell looks at events in biotech that could help the sector out of it's recent struggles. The Fast Money traders discuss the trade.
NBC News' Andrea Mitchell reports Turing Pharmaceuticals CEO Martin Shkreli will lower the price of Daraprim, which was raised 5,000 percent over the weekend. He says it will happen in the next few weeks.
A huge overnight price increase for an important tuberculosis drug has been rescinded after a public outcry, the NYT reports.
Kevin Gorman, Ph. D., President, CEO, Neurocrine Biosciences, explains how his company is up 144 percent so far this year.
Peder Holk Nielsen, CEO of Novozymes, says it has become tougher for renewables and biofuels to compete with fossil fuels.
Short sellers are continuing to target biotechnology stocks as one of the frothiest sectors in US equities staggers after a bruising August.
CNBC's Meg Tirrell reports on what could be a new era for U.S. medicine.
Fred Hassan, managing director of healthcare and consumer for Warburg Pincus, says we will see more M&A in the health care sector.
Discussing which biotechs may have been oversold in the selloff, with Michael Yee, RBC Capital biotech analyst.
David Seaburg, Cowen & Company, and Craig Johnson, Piper Jaffray & Co, discuss biotech, a formerly hot sector that's down more than 7 percent in a month.
One biotech stock could see massive moves later this month, thanks to the meddling of hedge fund heavy hitter, Kyle Bass. CNBC's Meg Tirrell reports the latest.